Journal of Surgical Research
Volume 163, Issue 1 , Pages e11-e15 , September 2010

Immuno-Expression of Human Melanoma Stem Cell Markers in Tissues at Different Stages of the Disease

  • Bhuvnesh K. Sharma, Ph.D.

      Affiliations

    • Maryland Melanoma Center, Franklin Square Hospital Center, Baltimore, Maryland
    • ,
  • Vinod Manglik, Ph.D.

      Affiliations

    • Elizabeth City State University, Elizabeth City, North Carolina
    • ,
  • E. George Elias, M.D., Ph.D.

      Affiliations

    • Maryland Melanoma Center, Franklin Square Hospital Center, Baltimore, Maryland
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Maryland Melanoma Center, Weinberg Cancer Institute, Suite 2300, 9103 Franklin Square Hospital Drive, Baltimore, MD 21237.

Received 7 January 2010

References 

  1. Strizzi L, Abbott DE, Salomon DS, et al. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle. 2008;7:1931
  2. Massard C, Deutsch E, Soria JC. Tumor stem cell-targeted treatment: Elimination or differentiation. Ann Oncol. 2006;17:1620
  3. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821
  4. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100:15178
  5. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature. 2004;432:396
  6. Clarke MF, Fuller M. Stem cells and cancer. Two faces of Eve. Cell. 2006;124:11111
  7. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43:935
  8. Wang Q, Chen Z, Du CZ, et al. Cancer stem cell marker CD133+ tumor cells and clinical outcome in rectal cancer. Histopathology. 2009;55:284
  9. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345
  10. Grichnik JM. Genomic instability and tumor stem cells. J Invest Dermatol. 2006;126:1214
  11. La Porta Caterina AM. Drug resistance in melanoma: New perspectives. Curr Med Chem. 2007;14:1
  12. Frank NY, Margaryan A, Huang Y, et al. ABCB5- mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65:4320
  13. Van kempen LC, Van den Oord JJ, VanMuijen GN, et al. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000;156:769
  14. Yamane T, Hayashi S, Mizoguchi M, et al. Derivation of melanocytes from embryonic stem cells in culture. Dev Dyn. 1999;216:450
  15. Kawa Y, Ito M, Ono H, et al. Stem cell factor and/or endothelin-3 dependent immortal melanoblast and melanocytes populations derived from mouse neural crest cells. Pigment Cell Res. 2000;13:73
  16. Bennett DC. Human melanocytes senescence and melanoma susceptibility genes. Oncogene. 2003;22:3063
  17. Hussein MR. Genetic pathways to melanoma tumorigenesis. J Clin Pathol. 2004;57:797
  18. Grichnik JM, Burch JA, Schulteis RD, et al. Melanoma, a tumor based on a mutant stem cell?. J Invest Dermatol. 2006;126:142
  19. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer and cancer stem cells. Nature. 2001;414:105

PII: S0022-4804(10)00242-8

doi: 10.1016/j.jss.2010.03.043

Journal of Surgical Research
Volume 163, Issue 1 , Pages e11-e15 , September 2010

Article Tools

* Image Usage & Resolution